Davide Rossi

15PUBLICATIONS
84CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Sep 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Jan-Michel Heger, Laman Mammadova, Julia Mattlener

|Jan 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

|Nov 16, 2021
Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia.

Erika Tissino, Eliana Pivetta, Alessandra Capuano

Pageof 3

Frequent Collaborators

4 joint publications

Alessandra Tedeschi

4 joint publications

Emanuele Zucca

3 joint publications

Chiara Tarantelli

3 joint publications

Sara Napoli